Literature DB >> 9797225

In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae.

G A Pankuch1, S A Jueneman, T A Davies, M R Jacobs, P C Appelbaum.   

Abstract

Selection of resistance to amoxicillin (with or without clavulanate), cefaclor, cefuroxime, and azithromycin among six penicillin G- and azithromycin-susceptible pneumococcal strains and among four strains with intermediate penicillin sensitivities (azithromycin MICs, 0.125 to 4 microg/ml) was studied by performing 50 sequential subcultures in medium with sub-MICs of these antimicrobial agents. For only one of the six penicillin-susceptible strains did subculturing in medium with amoxicillin (with or without clavulanate) lead to an increased MIC, with the MIC rising from 0.008 to 0.125 microg/ml. Five of the six penicillin-susceptible strains showed increased azithromycin MICs (0.5 to >256.0 microg/ml) after 17 to 45 subcultures. Subculturing in medium with cefaclor did not affect the cefaclor MICs of three strains but and led to increased cefaclor MICs (from 0.5 to 2.0 to 4.0 microg/ml) for three of the six strains, with MICs of other beta-lactams rising 1 to 3 twofold dilutions. Subculturing in cefuroxime led to increased cefuroxime MICs (from 0.03 to 0.06 microg/ml to 0.125 to 0.5 microg/ml) for all six strains without significantly altering the MICs of other beta-lactams, except for one strain, which developed an increased cefaclor MIC. Subculturing in azithromycin did not affect beta-lactam MICs. Subculturing of the four strains with decreased penicillin susceptibility in amoxicillin (with or without clavulanate) or cefuroxime did not select for beta-lactam resistance. Subculturing of one strain in cefaclor led to an increase in MIC from 0.5 to 2.0 microg/ml after 19 passages. In contrast to strains that were initially azithromycin susceptible, which required >10 subcultures for resistance selection, three of four strains with azithromycin MICs of 0.125 to 4.0 microg/ml showed increased MICs after 7 to 13 passages, with the MICs increasing to 16 to 32 microg/ml. All azithromycin-resistant strains were clarithromycin resistant. With the exception of strains that contained mefE at the onset, no strains that developed resistance to azithromycin contained ermB or mefE, genes that have been found in macrolide-resistant pneumococci obtained from clinic patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797225      PMCID: PMC105965     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

2.  In-vitro development of resistance to beta-lactam antibiotics in Streptococcus pneumoniae.

Authors:  H Carsenti-Etesse; J Durant; F De Salvador; M Bensoussan; F Bensoussan; C Pradier; A Thabaut; P Dellamonica
Journal:  J Antimicrob Chemother       Date:  1995-08       Impact factor: 5.790

Review 3.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  Detection of erythromycin-resistant determinants by PCR.

Authors:  J Sutcliffe; T Grebe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

5.  mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae.

Authors:  A Tait-Kamradt; J Clancy; M Cronan; F Dib-Hajj; L Wondrack; W Yuan; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

6.  Emergence of drug-resistant pneumococcal infections in the United States.

Authors:  R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

7.  Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.

Authors:  L M Ednie; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

8.  Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study.

Authors:  F Baquero
Journal:  J Antimicrob Chemother       Date:  1996-07       Impact factor: 5.790

Review 9.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

10.  Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae.

Authors:  R Muñoz; T J Coffey; M Daniels; C G Dowson; G Laible; J Casal; R Hakenbeck; M Jacobs; J M Musser; B G Spratt
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

View more
  25 in total

1.  Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.

Authors:  T A Davies; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

3.  In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.

Authors:  T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Effect of amoxicillin use on oral microbiota in young children.

Authors:  D Ready; H Lancaster; F Qureshi; R Bedi; P Mullany; M Wilson
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

5.  Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.

Authors:  Paul F Riska; Andrei Kutlin; Patrick Ajiboye; Arnold Cua; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.

Authors:  T A Davies; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

7.  Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy.

Authors:  A R H van Zanten; M Oudijk; M K E Nohlmans-Paulssen; Y G van der Meer; A R J Girbes; K H Polderman
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

8.  Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.

Authors:  Klaudia Kosowska-Shick; Kim L Credito; Glenn A Pankuch; Bonifacio DeWasse; Pamela McGhee; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

9.  Outer membrane protein STM3031 (Ail/OmpX-like protein) plays a key role in the ceftriaxone resistance of Salmonella enterica serovar Typhimurium.

Authors:  Wensi S Hu; Jing-Fang Lin; Ying-Hsiu Lin; Hsin-Yu Chang
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

10.  Antistreptococcal activity of AR-709 compared to that of other agents.

Authors:  Kathy Smith; Lois M Ednie; Peter C Appelbaum; Stephen Hawser; Sergio Lociuro
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.